Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease. Traditionally, attention has focused on the motor symptomatology of PD, but …

… Tanya Simuni has served as a consultant and received consulting fees from Acadia,
Abbvie, Allergan, Anavex, Avid, GE Medical, Eli Lilly and Company, Harbor, Ibsen, IMPAX, …

This study was undertaken to determine the prevalence and correlates of cognitive impairment
(CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's …

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …

Background Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …

The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling
the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Importance We observed a significant correlation between cerebrospinal fluid (CSF) levels
of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of …

Importance Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of
sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in …